FDA Continues Strong Support of Innovation in Development of Gene Therapy Products

On 28 January 2020 FDA announced that it continues its efforts to support innovators developing gene therapy products.

To date, the FDA has approved four gene therapy products, which insert new genetic material into a patient’s cells. The agency anticipates many more approvals in the coming years, as evidenced by the more than 900 investigational new drug (IND) applications for ongoing clinical studies in this area. The FDA believes this will provide patients and providers with increased therapeutic choices.

Read more online
Copyright Widler & Schiemann AG 2015. All Rights Reserved. /